• Something wrong with this record ?

Survival in melanoma in the nordic countries into the era of targeted and immunological therapies

F. Tichanek, A. Försti, A. Hemminki, O. Hemminki, K. Hemminki

. 2023 ; 186 (-) : 133-141. [pub] 20230324

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011206

OBJECTIVES: Survival in melanoma has been increasing and the most recent interest is to observe the population-level impact of novel targeted therapies and immunotherapy. We analysed survival in melanoma from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) over a 50-years period (1971-2020). METHODS: Relative 1-5/1- and 5-year survival data were obtained from the NORDCAN database for the years 1971-2020. We estimated annual changes in survival rates and determined significant breaking points for trends. RESULTS: Survival in melanoma has reached the point where 1-year survival is approaching 100% (men 97.5-98.6%, women 98.4-99.3%, depending on the country) and 5-year survival is 93% for men (91.5-95.2%) and 96% for women (95.3-97.2%). The highest survival figures were for DK. Significant increases in both 1- and 5-year survival were observed in most countries even towards the end of the follow-up (from 2006 to 2010-2011-2015 and further to 2016-2020). CONCLUSIONS: The main increase in melanoma survival took place up to year 1990, which was probably largely achieved through successful population campaigns for sun protection and programmes for early detection of lesions. Survival increased again after year 2000 up to the last period 2016-2020. This late development coincided with the introduction of targeted therapies using BRAF and BRAF/MEK inhibitors, and towards the end of the time period availability of checkpoint inhibitors. The success of melanoma treatment in DK was mostly likely due to the efficient use of modern therapies and to the centralised treatment for metastatic disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011206
003      
CZ-PrNML
005      
20230801132857.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2023.03.019 $2 doi
035    __
$a (PubMed)37068406
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tichanek, Filip $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, 30605 Pilsen, Czech Republic; Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Survival in melanoma in the nordic countries into the era of targeted and immunological therapies / $c F. Tichanek, A. Försti, A. Hemminki, O. Hemminki, K. Hemminki
520    9_
$a OBJECTIVES: Survival in melanoma has been increasing and the most recent interest is to observe the population-level impact of novel targeted therapies and immunotherapy. We analysed survival in melanoma from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) over a 50-years period (1971-2020). METHODS: Relative 1-5/1- and 5-year survival data were obtained from the NORDCAN database for the years 1971-2020. We estimated annual changes in survival rates and determined significant breaking points for trends. RESULTS: Survival in melanoma has reached the point where 1-year survival is approaching 100% (men 97.5-98.6%, women 98.4-99.3%, depending on the country) and 5-year survival is 93% for men (91.5-95.2%) and 96% for women (95.3-97.2%). The highest survival figures were for DK. Significant increases in both 1- and 5-year survival were observed in most countries even towards the end of the follow-up (from 2006 to 2010-2011-2015 and further to 2016-2020). CONCLUSIONS: The main increase in melanoma survival took place up to year 1990, which was probably largely achieved through successful population campaigns for sun protection and programmes for early detection of lesions. Survival increased again after year 2000 up to the last period 2016-2020. This late development coincided with the introduction of targeted therapies using BRAF and BRAF/MEK inhibitors, and towards the end of the time period availability of checkpoint inhibitors. The success of melanoma treatment in DK was mostly likely due to the efficient use of modern therapies and to the centralised treatment for metastatic disease.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a protoonkogenní proteiny B-raf $7 D048493
650    12
$a melanom $x terapie $7 D008545
650    _2
$a míra přežití $7 D015996
650    _2
$a imunoterapie $7 D007167
651    _2
$a Skandinávie a severské státy $x epidemiologie $7 D012537
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Finland; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Finland; Department of Urology, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, 30605 Pilsen, Czech Republic; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. Electronic address: k.hemminki@dkfz.de
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 186, č. - (2023), s. 133-141
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37068406 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132853 $b ABA008
999    __
$a ok $b bmc $g 1963540 $s 1197471
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 186 $c - $d 133-141 $e 20230324 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options